Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Materiobiology-guided regulation of mesenchymal stromal cell fate for aging-related diseases: From basic parameter design to clinical application

Feng Y., Qiu Y., Zhang S., Dai K., Wang J., Liu C.

Narrative Review on Osteoarthritis, Cardiovascular Disease, Chronic Wound, Immune Modulation, published in Bioact Mater (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Bioact Mater (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41799951
PMCID
PMC12963921
DOI
10.1016/j.bioactmat.2026.02.034

Abstract (original English)

Mesenchymal stromal cells (MSCs) possess potent immunomodulatory, pro-angiogenic, and regenerative capacities, offering broad clinical promise in regenerative medicine. However, clinical application is constrained by low in vivo survival, poor targeting, variable efficacy, replicative senescence and insufficiently characterized in vivo cell fate. The accelerating global aging trend further complicates MSC therapy for age-associated diseases. Biomaterials have emerged as powerful tools to enhance MSC function and direct cell fate. This review adopts a materiobiology perspective to detail how biomaterial design-across physical (stiffness, topography), chemical (surface chemistry, ion release), and biological (growth factor release, gene delivery) parameters, can proactively steer MSC fate and function to amplify therapeutic efficacy. Subsequently, focusing on the characteristics of aging-related diseases from three perspectives-reactive oxygen species scavenging, epigenetic regulation, and telomere protection-this review summarizes the anti-aging functional design of biomaterials. To bridge biomaterial-driven MSC regulation with in vivo therapeutic outcomes, we systematically review post-transplant fate-tracking technologies, including imaging-based approaches (MRI, CT, fluorescent probes) and transcriptomic monitoring, which enable quantitative evaluation and causal understandin

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research